theMednetRegister

Hepatology

General Hepatology   

Questions discussed in this category

Do you avoid peritoneal dialysis in cirrhotic patients with ascites?
3 Answers available
How do you determine whether to limit volume removal during therapeutic paracentesis in a patient without acute or chronic kidney disease?
3 Answers available
In patients with MASLD and F2–F3 fibrosis, would you initiate Resmetirom even if they are not making active lifestyle changes?
And for how long?
2 Answers available
What is your strategy to manage peri-procedural bleeding risk in patients with cirrhosis?
Do you use TEG or ROTEM? How do you counsel proceduralists on the unique hemostatic profile of patients with cirrhosis?
1 Answer available
How do you approach the workup for a patient with imaging showing features suggestive of cirrhosis?
2 Answers available
How do you approach dosing beta blockers for variceal prophylaxis when the standard dose doesn’t achieve the target heart rate?"
1 Answer available
Is there a serum ammonium level for which you recommend initiation of dialysis in a patient with hepatic encephalopathy?
3 Answers available
How do you decide whether ordering a 5' nucleotidase or a GGT is the most appropriate option in the evaluation of an elevated alkaline phosphatase?
1 Answer available
What is your approach to a patient with an elevated alkaline phosphatase level, but negative PBC serologies and normal biliary imaging?
1 Answer available
At what BMI or waist-circumference threshold do you opt to move from Fibroscan to other NILDA for fibrosis assessment?
And what would be your choice?
1 Answer available
How do you approach HCC screening in patients with advanced fibrosis e.g., F3 on FibroScan?
1 Answer available
When giving albumin challenge, for acute kidney injury with suspected hepatorenal syndrome, do you administer a single dose daily or split the dose of albumin?
1 Answer available
Do you recommend starting naltrexone at discharge for alcohol use disorder in patients with decompensated cirrhosis secondary to alcohol use?
2 Answers available
What is your clinical approach to the evaluation of cytopenias in patients with end-stage liver disease?
1 Answer available
How do you approach the use of viscoelastic assays (ex: TEG, ROTEM) in patients with identified coagulopathy in the peri-procedural period?
1 Answer available
What parameters would you use to monitor and interpret iron levels in a hemochromatosis patient where ferritin is unreliable due to underlying chronic inflammation?
How would your recommendation change if the patient has H63 homozygous mutation?
2 Answers available
When would you consider use of EUS guided liver biopsy over percutaneous and/or transjugular?
2 Answers available
If you do not have easy access to shear wave elastography (aka Fibroscan), what do you recommend for non-invasive tests to determine if a MASLD patient has clinically significant portal hypertension and risk-stratify them?
1 Answer available
How do you approach a patient who has incidentally found liver and renal cysts?
1 Answer available
Do you obtain liver biopsy to confirm the diagnosis of cirrhosis if cirrhotic liver morphology is noted on imaging?
2 Answers available
How do you choose between resmetirom and semaglutide in the treatment of MASH?
1 Answer available
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
1 Answer available


Papers discussed in this category

Lancet (London, England), 2015-03-14
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
The New England journal of medicine, 2020 Nov 13
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Gastroenterology, 2015 Apr 10
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
The New England journal of medicine, 2010 Apr 28
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Hepatology (Baltimore, Md.), 2022 Jan 24
Placebo effect on progression and regression in NASH: Evidence from a meta-analysis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2021 Jun 04
The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained.
The New England journal of medicine, 2024 Feb 08
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Hepatology (Baltimore, Md.), 2024 Oct 18
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.
Clinical journal of the American Society of Nephrology : CJASN, 2023 Oct 17
How We Treat Hyperammonemia in Acute Liver Failure.
International journal of molecular sciences, 2022 Mar 13
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.
Hepatology (Baltimore, Md.), 2012 Apr
Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials.
Medicine, 2016 Jan
Peritoneal Dialysis is Associated With A Better Survival in Cirrhotic Patients With Chronic Kidney Disease.
Clinical nephrology, 2011 Oct
Outcome of peritoneal dialysis in cirrhotic patients with end-stage renal disease: a 24-years' experience in Taiwan.
The American journal of medicine, 1992 Jul
Peritoneal dialysis in end-stage renal disease patients with preexisting chronic liver disease and ascites.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002 Jul
Outcome of peritoneal dialysis in cirrhotic patients with chronic renal failure.
Hepatology (Baltimore, Md.), 2023 Oct 23
AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis.
The New England journal of medicine, 2021 Mar 04
A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis.
Hepatology (Baltimore, Md.), 2012-01
Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients.
Clinical and translational gastroenterology, 2019 Apr
Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions!

Related Topics in Hepatology

Copyright © 2025 theMednet
All Rights Reserved.